The radioisotope platform provides comprehensive capabilities for the non-clinical and clinical evaluation of radiopharmaceuticals and radioisotope-labeled compounds. With the qualification to use 36 different radioisotopes, the platform supports a range of studies, including ADME research, human material balance studies, molecular imaging, and radiopharmaceutical evaluations. The platform is equipped with state-of-the-art experimental facilities and equipment, including a γ counter, liquid scintillation counter, QWBA, PET/MR imaging, and other advanced testing technologies. It supports a variety of animal models, including mouse, rat, rabbit, dog, pig, and non-human primates, and provides end-to-end analysis of radioactive biological samples.
Certified by NMPA, OECD, and FDA, the platform strictly follows GLP/GCP international standards, providing whole-process solutions that meet global standards for innovative drug development. The platform's capabilities are bolstered by its three-dimensional advantages of qualification, hardware, and technology.